Bar-Shalom Rachel, Yefremov Nikolai, Guralnik Ludmila, Gaitini Diana, Frenkel Alex, Kuten Abraham, Altman Hernan, Keidar Zohar, Israel Ora
Department of Nuclear Medicine, Rambam Medical Center, Haifa 35254, Israel.
J Nucl Med. 2003 Aug;44(8):1200-9.
This study assessed the clinical performance of a combined PET/CT system using (18)F-FDG in oncologic patients.
(18)F-FDG PET/CT was used to evaluate 204 patients with 586 suspicious lesions. All patients had available follow-up data, enabling assessment of the clinical significance of hybrid PET/CT findings. Differences in interpretation between PET, CT, and fused PET/CT data were prospectively documented for detection, localization, and characterization of each evaluated site. The additional value of PET/CT for data interpretation over that of separate PET and CT was classified into several criteria, including change in lesion characterization to either definitely benign or definitely malignant, precise anatomic localization of malignant (18)F-FDG uptake, and retrospective lesion detection on PET and CT. The clinical impact of information provided by PET/CT on patient management was assessed on the basis of follow-up data concerning further diagnostic or therapeutic approach. Analysis of data was performed for the whole study population, for different types of cancer, and for different anatomic sites.
PET/CT provided additional information over the separate interpretation of PET and CT in 99 patients (49%) with 178 sites (30%). PET/CT improved characterization of equivocal lesions as definitely benign in 10% of sites and as definitely malignant in 5% of sites. It precisely defined the anatomic location of malignant (18)F-FDG uptake in 6%, and it led to retrospective lesion detection on PET or CT in 8%. The results of PET/CT had an impact on the management of 28 patients (14%). Hybrid PET/CT data obviated the need for further evaluation in 5 patients, guided further diagnostic procedures in 7 patients, and assisted in planning therapy for 16 patients.
Hybrid PET/CT improves the diagnostic interpretation of (18)F-FDG PET and CT in cancer patients and has an impact on both diagnostic and therapeutic aspects of patient management.
本研究评估了使用(18)F-FDG的联合PET/CT系统在肿瘤患者中的临床性能。
(18)F-FDG PET/CT用于评估204例患者的586个可疑病变。所有患者均有可用的随访数据,从而能够评估PET/CT融合成像结果的临床意义。前瞻性记录PET、CT和融合PET/CT数据在每个评估部位的检测、定位和特征描述方面的解读差异。PET/CT相对于单独的PET和CT在数据解读方面的附加价值分为几个标准,包括病变特征转变为明确良性或明确恶性、恶性(18)F-FDG摄取的精确解剖定位以及PET和CT上的回顾性病变检测。基于关于进一步诊断或治疗方法的随访数据,评估PET/CT提供的信息对患者管理的临床影响。对整个研究人群、不同类型癌症以及不同解剖部位进行数据分析。
在99例患者(49%)的178个部位(30%)中,PET/CT相对于单独解读PET和CT提供了额外信息。PET/CT将10%的部位的可疑病变特征明确为良性,5%的部位明确为恶性。它在6%的部位精确确定了恶性(18)F-FDG摄取的解剖位置,并且在8%的部位导致了PET或CT上的回顾性病变检测。PET/CT的结果对28例患者(14%)的管理产生了影响。PET/CT融合成像数据使5例患者无需进一步评估,指导7例患者进行进一步诊断程序,并协助16例患者制定治疗计划。
PET/CT融合成像改善了癌症患者中(18)F-FDG PET和CT的诊断解读,并对患者管理的诊断和治疗方面均有影响。